BioGaia

Regulatory Filings • Jan 11, 2011

Press release 11th January 2011

BioGaia signs agreement for its new Oral Rehydration Solution product for Greece

BioGaia has signed an agreement with Cube Pharmaceuticals giving the company exclusive rights to distribute BioGaia´s new Oral Rehydration Solution (ORS) product with Lactobacillus reuteri Protectis in Greece. Launch is planned for summer 2011.

Cube Pharmaceutical, with 25 sales representatives, was founded in 2004 and is a growing company in sales of pharmaceuticals and nutritional products in Greece.

• The unique combination ORS, being the first worldwide, conveniently combining the effects of ORS, probiotic and zinc, is one more proof of BioGaia´s innovative profile, says Evagelos Kalofolia, Managing Director, Cube Pharmaceutical.

• It is gratifying that our new, unique oral rehydration product with Reuteri in portion packs will be launched in one further market, says Peter Rothschild, Managing Director, BioGaia.

ORS was developed 50 years ago and has since then been the basis of a modern treatment of, amongst other indications, children's diarrhoea and gastroenteritis caused by cholera or rotavirus. WHO and UNICEF, who together determine the official guidelines for the composition of oral rehydration solutions, have also recommended a parallel intake of zinc for the treatment of diarrhoea, particularly in small children. BioGaia´s probiotic ORS product contains Lactobacillus reuteri Protectis, oral rehydration solution and zinc all ready-mixed in one portion pack.

BioGaia´s ORS product is already sold in Sweden and Italy.

For additional information contact: Peter Rothschild, President, BioGaia: +46 8 555 293 00

Latest press releases from BioGaia:

2010-12-08 New study published: Lactobacillus reuteri Protectis reduced regurgitation and improved stomach emptying in infants 2010-11-10 New study published: Lactobacillus reuteri Prodentis effective in the treatment of periodontitis 2010-10-27 Interim report 1 January - 30 September 2010

BioGaia publishes this information in accordance with the Swedish Securities Markets Act. The information was published on January 11, 2011, at 10:00 AM CET.

BioGaia is a biotechnology company that develops, markets and sells probiotic products with documented health benefits. The products are primarily based on the lactic acid bacterium Lactobacillus reuteri, which has probiotic, health-enhancing effects. The class B share of the Parent Company BioGaia AB is quoted on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm. www.biogaia.com